1. ������Ƥ����������
2. տ���㶫ҽѧԺ����ҽԺƤ����
3. ������Ƥ���Բ�������

��CD20����¡����Ŀǰ���������ƽ϶�����������Լ��������о�������������ݡ��������ƣ���ȡ��������Ч������ص��о���Ҫ����������������ݡ�����ݡ������Ѫ���׵�������ݡ�����е�Ӧ�ã������û�����δ��ȷ��Bϸ�����������Ϊ�벹��������ϸ�����Է�Ӧ����������ϸ���鵼��ϸ�������ü�ֱ���յ�B�ܰ�ϸ���������йء�������CD20����¡����Ŀǰ���о���չ���������������Լ�����ݡ�����е��ٴ�Ӧ�ã�ּ�ڽ�һ����ʾ�������ݡ�������Ƶ�֤�ݣ��Ӷ����õ��˽�����������ݡ������Ӧ�õ�ǰ����

Anti-CD20 monoclonal antibodies have been applied to the treatment of many autoimmune diseases and severe urticaria with favourable outcomes. Current researches about anti-CD20 monoclonal antibodies are focused on their application in refractory urticaria such as autoimmune urticaria and urticarial vasculitis. Their mechanism of action has not been defined. B cell depletion mechanism is considered to be associated with complement-dependent cytotoxicity, antibody dependent cellular cytotoxicity, direct induction of apoptosis, etc. This paper outlines the progress in researches on anti-CD20 monoclonal antibodies and their application in autoimmune diseases and urticaria, in order to provide evidence for their use in urticaria, and to predict their perspectives in the treatment of refractory urticaria.

��CD20����������ݡ���������еij����о�

�ο����� [1] Lindholm C, B?rjesson-Asp K, Zendjanchi K, et al. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus. J Rheumatol, 2008 ;35(5):826-833. [2] Pego-Reigosa JM, Lu TY, Fontanillo MF, et al. Long-term improvement of lipid profile in patients with refractory systemic lupus erythematosus treated with B-cell depletion therapy: a retrospective observational study. Rheumatology (Oxford), 2010 ( 4). [3] Tokunaga M�� Saito K��Kawabata D�� et a1��Efficacy of rituximab (anti—CD20) for refractor),systemic lupus erythematosus involving the central nervous system��Ann Rheum Dis 2007��66(4)��470-475�� [4] Podolskaya A��Stadermann M��Pilkington C��et a1��B cell depletion therapy for 19 patients with refractory systemic lupus erythematosus��Arch Dis Child��2008��93(5)��401—406�� [5] Alter M, Wittmann M, V?lker B, et al. Successful treatment of pemphigus foliaceus with rituximab. Report of 3 cases. Hautarzt. 2009 ,60(9):743-748�� [6] Sorce M, Aricò M, Bongiorno MR. Rituximab in refractory pemphigus vulgaris. Dermatol Ther. 2008 ,21 Suppl 1:S6-9. [7] Janisson-Dargaud D, Reguia? Z, Perceau G, et al. Juvenile pemphigus vulgaris. Ann Dermatol Venereol. 2008 ,135(12):843-847. [8] Reguia? Z, Tchen T, Perceau G, et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol. 2009 ,136(5):431-434.. [9] Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol ,156(1):194-196. [10] Chung L, Genovese MC, Fiorentino DF. A pilot trial of rituximab in the treatment of patients with dermatomyositis. Arch Dermatol,2007 ,143(6):763-767. [11] Cooper MA, Willingham DL, Brown DE, et al. Rituximab for the treatment of juvenile dermatomyositis: a report of four pediatric patients. Arthritis Rheum, 2007 ,56(9):3107-3111. [12] Haroon M,Devlin J.Rituximab as a first-line agent for the treatment of dermatomyositis.Rheumatol Int.2010,26.[Epub ahead of print] [13] Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol 2006,177:362-371. [14] Golay J, Cittera E, Di Gaetano N, Manganini M, Mosca M, Nebuloni M, et al. The role of complement in the therapeutic activity of rituximab in a murine B lymphoma model homing in lymph nodes. Haematologica 2006,91:176-183. [15] Li Y, Williams ME, Cousar JB, Pawluczkowycz AW, Lindorfer MA, Taylor RP. Rituximab-CD20 complexes are shaved from Z138 mantle cell lymphoma cells in intravenous and subcutaneous SCID mouse models. J Immunol 2007,179:4263-4271. [16] Beum PV, Kennedy AD, Williams ME, Lindorfer MA, Taylor RP. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes. J Immunol 2006, 176:2600-2609. [17] Glennie MJ, French RR, Cragg MS, Taylor RP. Mechanisms of killing by anti-CD20 monoclonal antibodies. Mol Immunol 2007,44:3823-3837. [18] Treon SP, Hansen M, Branagan AR, Verselis S, Emmanouilides C, Kimby E, et al. Polymorphisms in Fc!RIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenstrom's macroglobulinemia. J Clin Oncol 2005,23:474-481. [19] Julie A. Bowles, Siao-Yi Wang,et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood, 2006 , 108(8): 2648–2654. [20] Stolz C, Hess G, H?hnel PS, Grabellus F, Hoffarth S, Schmid KW, et al. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximabinduced apoptosis. Blood ,2008,112:3312-3321. [21] Cartron G, Watier H, Golay J, Solal-Celigny P. From the bench to the bedside: ways to improve rituximab efficacy. Blood ,2004,104:2635-2642. [22] Arkwright PD.Anti-CD20 or anti-IgE therapy for severe chronic autoimmune urticaria.J Allergy Clin Immunol , 2009 ,123(2):510-511. [23] Mallipeddi R, Grattan CE.Lack of response of severe steroid-dependent chronic urticaria to rituximab .Clin Exp Dermatol, 2007 ,32(3):333-334. [24] Mukhtyar C, Misbah S, Wilkinson J,et al.Refractory urticarial vasculitis responsive to anti-B-cell therapy.Br J Dermatol, 2009 ,160(2):470-472. [25] Murota H, Shoda Y, Ishibashi T,et al.Improvement of recurrent urticaria in a patient with Schnitzler syndrome associated with B-cell lymphoma with combination rituximab and radiotherapy.J Am Acad Dermatol, 2009 ,61(6):1070-1075. [26] Levi M, Hack CE, van Oers MH.Rituximab-induced elimination of acquired angioedema due to C1-inhibitor deficiency.Am J Med, 2006 ,119(8):e3-5. [27] Tokunaga M��Fujii K��Saito K��et a1��Down-regulation of CD40 and CD80 on B cells in patients with life-threatening systemic lupus erythematosus after successful treatment with fituximab fJ1��Rheumatology(Oxford)��2005��44(2)��176-182��